TrialLeukemia research2019

Efficacy and safety results from a phase 1b/2, multicenter, open-label study of oprozomib and dexamethasone in patients with relapsed and/or refractory multiple myeloma.

Parameswaran Hari et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.